Literature DB >> 24918006

Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease.

Delphine Labaere1, Annick Smismans1, August Van Olmen2, Paul Christiaens2, Geert D'Haens3, Veerle Moons2, Pieter-Jan Cuyle2, Johan Frans1, Peter Bossuyt2.   

Abstract

BACKGROUND AND OBJECTIVES: Faecal calprotectin is a valuable noninvasive marker for inflammatory bowel disease (IBD). The aim of our study was to determine the correlation between six different calprotectin assays and compare their performance for diagnosis and follow up of IBD.
METHODS: Thirty-one patients with suspected IBD and 31 patients in follow up were included. We determined calprotectin by means of three rapid immmunochromatographic tests, two enzyme-linked immunosorbent assays, and one automated fluoroimmunoassay. Results were correlated with endoscopic and histological findings.
RESULTS: Although all methods correlated significantly, slopes and intercepts differed extensively, with up to 5-fold quantitative differences between assays. Sensitivity and specificity for diagnosis of IBD were 82-83 and 84-89%, respectively. For follow up, sensitivity in detecting mild ulcerative colitis was 71-100%. In moderate-to-severe ulcerative colitis, sensitivity was 100% for all assays. Specificity was 67-86% in both subgroups. In Crohn's disease, only moderate-to-severe disease could be differentiated from remission, with sensitivity 83-86% and specificity 75% for all tests.
CONCLUSIONS: All calprotectin assays showed comparable clinical performance for diagnosis of IBD. For follow up, performance was acceptable, except for mild Crohn's disease. Because of the large quantitative differences, further efforts are needed to standardize calprotectin assays.

Entities:  

Keywords:  Calprotectin; Crohn’s disease; diagnosis; follow up; inflammatory bowel disease; ulcerative colitis

Year:  2014        PMID: 24918006      PMCID: PMC4040805          DOI: 10.1177/2050640613518201

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  16 in total

1.  Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin.

Authors:  Alberto Dolci; Mauro Panteghini
Journal:  Clin Chim Acta       Date:  2011-10-01       Impact factor: 3.786

2.  Fecal calprotectin: assessment of a rapid test.

Authors:  T A Vestergaard; S L Nielsen; J F Dahlerup; N Hornung
Journal:  Scand J Clin Lab Invest       Date:  2008       Impact factor: 1.713

3.  World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.

Authors:  Charles N Bernstein; Michael Fried; J H Krabshuis; Henry Cohen; R Eliakim; Suleiman Fedail; Richard Gearry; K L Goh; Saheed Hamid; Aamir Ghafor Khan; A W LeMair; Qin Ouyang; J F Rey; Ajit Sood; Flavio Steinwurz; Ole O Thomsen; Alan Thomson; Gillian Watermeyer
Journal:  Inflamm Bowel Dis       Date:  2010-01       Impact factor: 5.325

4.  Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

Authors:  Jennifer Jones; Edward V Loftus; Remo Panaccione; Li-Sheng Chen; Sandra Peterson; Joseph McConnell; Linnea Baudhuin; Karen Hanson; Brian G Feagan; Scott W Harmsen; Alan R Zinsmeister; Emelie Helou; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-17       Impact factor: 11.382

5.  Evaluation of the Quantum Blue® rapid test for faecal calprotectin.

Authors:  Julie Wassell; Michael Wallage; Ella Brewer
Journal:  Ann Clin Biochem       Date:  2011-09-19       Impact factor: 2.057

6.  Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.

Authors:  M De Vos; O Dewit; G D'Haens; F Baert; F Fontaine; S Vermeire; D Franchimont; T Moreels; D Staessen; L Terriere; B Vander Cruyssen; E Louis
Journal:  J Crohns Colitis       Date:  2011-12-11       Impact factor: 9.071

7.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

Review 8.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.

Authors:  James D Lewis
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

9.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.

Authors:  Taina Sipponen; Erkki Savilahti; Kaija-Leena Kolho; Hannu Nuutinen; Ulla Turunen; Martti Färkkilä
Journal:  Inflamm Bowel Dis       Date:  2008-01       Impact factor: 5.325

Review 10.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.

Authors:  Patrick F van Rheenen; Els Van de Vijver; Vaclav Fidler
Journal:  BMJ       Date:  2010-07-15
View more
  36 in total

1.  Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study.

Authors:  Takayuki Yamamoto; Takahiro Shimoyama; Satoru Umegae; Koichi Matsumoto
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

2.  Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Authors:  Anna-Maija Puolanne; Kaija-Leena Kolho; Henrik Alfthan; Ari Ristimäki; Harri Mustonen; Martti Färkkilä
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

Review 3.  Practical guidance on the use of faecal calprotectin.

Authors:  Matthew J Brookes; Simon Whitehead; Daniel R Gaya; Antony Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2017-02-22

Review 4.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 5.  The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease.

Authors:  Takayuki Yamamoto
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

Review 6.  Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease.

Authors:  Karoline Freeman; Brian H Willis; Ronan Ryan; Sian Taylor-Phillips; Aileen Clarke
Journal:  BMC Med Res Methodol       Date:  2022-07-12       Impact factor: 4.612

7.  Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis.

Authors:  Takayuki Yamamoto; Takahiro Shimoyama; Takuya Bamba; Koichi Matsumoto
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

8.  Inadequate Reporting of Analytical Characteristics of Biomarkers Used in Clinical Research: A Threat to Interpretation and Replication of Study Findings.

Authors:  Qian Sun; Kerry J Welsh; David E Bruns; David B Sacks; Zhen Zhao
Journal:  Clin Chem       Date:  2019-10-31       Impact factor: 8.327

9.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

10.  Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway.

Authors:  James Turvill; Daniel Turnock; Hayden Holmes; Alison Jones; Eleanor Mclaughlan; Victoria Hilton; Stacey Marriott
Journal:  Frontline Gastroenterol       Date:  2018-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.